David T Teachey
Overview
Explore the profile of David T Teachey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
178
Citations
11602
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
31.
Glisovic-Aplenc T, Diorio C, Chukinas J, Veliz K, Shestova O, Shen F, et al.
Blood Adv
. 2023 May;
7(16):4418-4430.
PMID: 37171449
Many hematologic malignancies are not curable with chemotherapy and require novel therapeutic approaches. Chimeric antigen receptor (CAR) T-cell therapy is 1 such approach that involves the transfer of T cells...
32.
Yoshimura S, Panetta J, Hu J, Li L, Gocho Y, Du G, et al.
Leukemia
. 2023 Apr;
37(6):1194-1203.
PMID: 37076694
LCK is a novel therapeutic target in ~40% of T-cell acute lymphoblastic leukemia (T-ALL), and dasatinib and ponatinib can act as LCK inhibitors with therapeutic effects. We herein report a...
33.
Diorio C, Teachey D, Canna S
J Allergy Clin Immunol Pract
. 2023 Mar;
11(6):1636-1644.
PMID: 36990432
Cytokine storm syndromes (CSS) represent a diverse group of disorders characterized by severe overactivation of the immune system. In the majority of patients, CSS arise from a combination of host...
34.
Chu Y, Gardenswartz A, Diorio C, Marks L, Lowe E, Teachey D, et al.
Best Pract Res Clin Haematol
. 2023 Mar;
36(1):101442.
PMID: 36907635
The prognosis is dismal (2-year overall survival less than 25%) for childhood, adolescent, and young adult (CAYA) with relapsed and/or refractory (R/R) non-Hodgkin lymphoma (NHL). Novel targeted therapies are desperately...
35.
Hines M, Knight T, McNerney K, Leick M, Jain T, Ahmed S, et al.
Transplant Cell Ther
. 2023 Mar;
29(7):438.e1-438.e16.
PMID: 36906275
T cell-mediated hyperinflammatory responses, such as cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), are now well-established toxicities of chimeric antigen receptor (CAR) T cell therapy. As...
36.
37.
Guolla L, Breitbart S, Foroutan F, Thabane L, Loh M, Teachey D, et al.
Blood
. 2023 Feb;
141(24):2944-2954.
PMID: 36821772
The benefit associated with the incorporation of vincristine-corticosteroid pulses in maintenance therapy for pediatric acute lymphoblastic leukemia (ALL) is unclear, particularly in the context of modern intensive therapy. This systematic...
38.
Gupta S, Dai Y, Chen Z, Winestone L, Teachey D, Bona K, et al.
Lancet Haematol
. 2023 Feb;
10(2):e129-e141.
PMID: 36725118
Background: Previous studies have identified racial and ethnic disparities in childhood acute lymphocytic leukaemia survival. We aimed to establish whether disparities persist in contemporaneous cohorts and, if present, are attributable...
39.
40.
Gossai N, Devidas M, Chen Z, Wood B, Zweidler-McKay P, Rabin K, et al.
Blood
. 2023 Jan;
141(15):1802-1811.
PMID: 36603187
To determine the prognostic significance of central nervous system (CNS) leukemic involvement in newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL), outcomes on consecutive, phase 3 Children's Oncology Group clinical trials...